• Vaccine Name: N. caninum NcMIC1 Protein Vaccine
• Target Pathogen: Neospora caninum
• Target Disease: Neosporosis
• Vaccine Ontology ID: VO_0011563
• Type: Subunit vaccine
• Status: Research
• MIC1 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001238
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: Group 1 was immunized 3 times with 100 μl recNcMIC1 (75 μg/ ml) emulsified in RIBI Adjuvant System (PBS-RAS; RIBI ImmunoChem Research, Inc., Hamilton, Montana) according to the manufacturer's recommendations. Inoculations were carried out by intraperitoneal (i.p.) injections of 200 μl of respective preparations. Group 2 was vaccinated 3 times with 100 μl of pcDNA-NcMIC1 (1 mg/ml) by i.m. injections (50 μg into each hind limb muscle). Group 3 was treated twice by i.m. pcDNA-NcMIC1 injections followed by 1 i.p. recNcMIC1 antigen. Control groups 4, 5, and 6 included corresponding treatments with PBS emulsified in RIBI adjuvant (i.p.), pcDNA3.1 (100 μg i.m., plasmid without insert), and PBS (= infection control, i.p. treatment), respectively. Vaccination started on day 0 and booster injections were administered at days 31 and 58, respectively (Alaeddine et al., 2005).
• Challenge Protocol: On day 100, all mice groups were challenged i.p. with 2 × 10^6 live N. caninum tachyzoites (NC1 strain) suspended in 100 μl PBS (Alaeddine et al., 2005).
• Efficacy: Despite the fact that cerebral infection occurred, none of the animals in the recNcMIC1-vaccinated group experienced clinical signs of disease during the 3-wk time frame. The recNcMIC1-vaccinated group showed a significant reduction of parasite number compared with the adjuvant control group (Alaeddine et al., 2005).